FDA Approves Rare Blood Disease Treatment Reblozyl Anemia, Approvals, Beta Thalassemia, Erythroid maturation agents, Fast Track Designation, FDA, FDA/Regulatory, Genetic Defects, Hemoglobin, Orphan Drug Designation, Red Blood Cell, Red blood cell (RBC) transfusions, Transfusions The U.S. FDA approved Celgene and Acceleron Pharma’s Reblozyl for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions. Read more November 11, 2019/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2019-11-11 12:18:452019-11-11 13:00:25FDA Approves Rare Blood Disease Treatment Reblozyl
